Jefferies says Viking Therapeutics (VKTX) reported “class-leading weight loss” in its Phase 2 oral drug trial as well as “good maintenance” and argues that the market is “overreacting” on the gastrointestinal adverse event discontinuation profile, while “underappreciating that it could be modulated by dosing optimization.” The firm keeps a Buy rating and $101 price target on Viking shares, which are down 41% to $24.64 in afternoon trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics’ VK2735: Promising Phase 2 Results Highlight Strong Market Potential and Commercial Viability
- Stifel says buy Viking Therapeutics following ‘overreaction’ to Phase 2 outcome
- Viking Therapeutics: Buy Rating Affirmed Amid Promising VK2735 Trial Results and Market Overreaction
- Viking Therapeutics falls -42.6%
- Viking Therapeutics drop may be partially ‘sell the news,’ says H.C. Wainwright